World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
78
Citations
18490
World Ranking
1779
National Ranking
68

Roberto Gerli publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Roberto Gerli sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 486 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Roberto Gerli D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Roberto Gerli sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Roberto Gerli is affiliated with the University of Perugia in Italy. Their research primarily spans the field of Medicine, with a notable focus on Rheumatology, Physiology, Genetics, Pathology and Forensic Medicine, and Immunology.

The scientist's work addresses several key topics, including:

  • Salivary Gland Disorders and Functions
  • Systemic Lupus Erythematosus Research
  • Systemic Sclerosis and Related Diseases
  • Salivary Gland Tumors Diagnosis and Treatment
  • Rheumatoid Arthritis Research and Therapies
  • Monoclonal and Polyclonal Antibodies Research
  • Fibromyalgia and Chronic Fatigue Syndrome Research

Roberto Gerli has contributed to a variety of scholarly articles. Selected recent papers include:

  • COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy, 2020, Immunologic Research
  • The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19, 2020, Journal of Autoimmunity
  • Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting, 2020, Arthritis & Rheumatology
  • Immune checkpoint inhibitors-induced autoimmunity: The impact of gender, 2020, Autoimmunity Reviews
  • The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus, 2020, Autoimmunity Reviews

The scientist's frequent co-authors reflect collaboration within the rheumatology and immunology research communities. Regular collaborators include:

  • Elena Bartoloni
  • Carlo Perricone
  • Giacomo Cafaro
  • Roberto Giacomelli
  • Francesco Carubbi

Publishing predominantly in journals relevant to rheumatology and autoimmune diseases, Roberto Gerli's work appears often in these venues:

  • Annals of the Rheumatic Diseases
  • Clinical and Experimental Rheumatology
  • Autoimmunity Reviews
  • Reumatismo
  • Lara D. Veeken

Best Publications

  • Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases

    Yehuda Shoenfeld;Roberto Gerli;Andrea Doria;Eiji Matsuura

  • Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.

    C Vitali;S Bombardieri;H M Moutsopoulos;J Coll

  • Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity

    G Vaudo;S Marchesi;R Gerli;R Allegrucci

  • Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial

    Clodoveo Ferri;Clodoveo Ferri;Emanuele Marzo;Emanuele Marzo;Giovanni Longombardo;Giovanni Longombardo;Francesco Lombardini;Francesco Lombardini

  • CD4+CD28− T Lymphocytes Contribute to Early Atherosclerotic Damage in Rheumatoid Arthritis Patients

    Roberto Gerli;Giuseppe Schillaci;Andrea Giordano;Elena Bartoloni Bocci

  • Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients

    Chiara Baldini;Pasquale Pepe;Luca Quartuccio;Roberta Priori

  • Prednisone plus Methotrexate for Polymyalgia Rheumatica: A Randomized, Double-Blind, Placebo-Controlled Trial

    Roberto Caporali;Marco A. Cimmino;Gianfranco Ferraccioli;Roberto Gerli

  • Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients

    Claudio Vitali;Gianluigi Palombi;Chiara Baldini;Maurizio Benucci

  • Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial

    Carlo Salvarani;PierLuigi Macchioni;Carlo Manzini;Giuseppe Paolazzi

  • Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.

    Pilar Brito-Zerón;Pilar Brito-Zerón;Nihan Acar-Denizli;Margit Zeher;Astrid Rasmussen

  • Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

    Fabiola Atzeni;Piercarlo Sarzi-Puttini;Costantino Botsios;Antonio Carletto

  • Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

    Francesco Carubbi;Paola Cipriani;Alessandra Marrelli;Paola Di Benedetto

  • Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

    Lorenzo Cavagna;Ernesto Trallero-Araguás;Federica Meloni;Ilaria Cavazzana

  • COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.

    Carlo Perricone;Elena Bartoloni;Roberto Bursi;Giacomo Cafaro

  • Ultrasonography of salivary glands in primary Sjögren's syndrome: a comparison with contrast sialography and scintigraphy

    F. Salaffi;M. Carotti;A. Iagnocco;F. Luccioli

  • Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population‐based multicentre cohort study

    E. Bartoloni;C. Baldini;G. Schillaci;L. Quartuccio

  • Precocious intima-media thickening in patients with primary Sjögren's syndrome

    Gaetano Vaudo;Elena Bartoloni Bocci;Yehuda Shoenfeld;Giuseppe Schillaci

  • Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new.

    Alessia Alunno;Elena Bartoloni;Onelia Bistoni;Giuseppe Nocentini

  • Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.

    Luana Mancarella;Francesca Bobbio-Pallavicini;Fulvia Ceccarelli;Paola Chiara Falappone

  • Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone.

    V Bocci;G Valacchi;F Corradeschi;C Aldinucci

Frequent Co-Authors

Alessia Alunno
Alessia Alunno University of L'Aquila
Roberto Giacomelli
Roberto Giacomelli Campus Bio Medico University Hospital
Luca Quartuccio
Luca Quartuccio University of Udine
Guido Valesini
Guido Valesini Sapienza University of Rome
Stefano Bombardieri
Stefano Bombardieri University of Pisa
Paola Cipriani
Paola Cipriani University of L'Aquila
Andrea Doria
Andrea Doria University of Padua
Carlomaurizio Montecucco
Carlomaurizio Montecucco University of Pavia
Carlo Salvarani
Carlo Salvarani University of Modena and Reggio Emilia
Angela Tincani
Angela Tincani University of Brescia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often involves exploring related healthcare fields, particularly nursing and specialized practitioner roles. For those interested in entering the healthcare sector quickly, finding which LPN programs are easiest to get into can be a crucial first step. Licensed Practical Nurse (LPN) programs offer a solid foundation for clinical work and often serve as a stepping stone toward advanced nursing roles.

Advancing beyond the LPN level, many students consider Nurse Practitioner (NP) programs to deepen their expertise and expand their career opportunities. For individuals seeking a streamlined path, understanding the easiest NP programs to get into helps minimize barriers to entry while maintaining quality education standards.

For those drawn to mental health within the immunology and healthcare continuum, specialized training is available. The best psychiatric mental health nurse practitioner programs online offer excellent clinical placements, ensuring students gain practical experience essential for this challenging field.

Cost is also a significant factor for many students. Exploring the cheapest PMHNP programs can make advanced mental health training more accessible without sacrificing quality.

These related online degrees and career pathways provide flexible options for aspiring healthcare professionals who want to complement their immunology knowledge with practical skills and credentials.

Best Scientists Citing Roberto Gerli

Trending Scientists

Recently Published Articles